Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.09
-0.23 (-3.14%)
At close: Apr 28, 2026, 4:00 PM EDT
7.18
+0.09 (1.27%)
After-hours: Apr 28, 2026, 7:19 PM EDT
Seres Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.79 | - | - | - | 144.93 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | 336.33% | Upgrade
|
| Cost of Revenue | 55.6 | 68.13 | 117.6 | 13.43 | 141.89 | Upgrade
|
| Gross Profit | -54.82 | -68.13 | -117.6 | -13.43 | 3.04 | Upgrade
|
| Selling, General & Admin | 39.16 | 53.18 | 77.5 | 70.26 | 69.26 | Upgrade
|
| Research & Development | - | - | - | 96.22 | - | Upgrade
|
| Other Operating Expenses | - | - | - | - | -1.73 | Upgrade
|
| Operating Expenses | 39.16 | 53.18 | 77.5 | 166.49 | 67.53 | Upgrade
|
| Operating Income | -93.97 | -121.32 | -195.1 | -179.91 | -64.49 | Upgrade
|
| Interest Expense | - | - | -2.47 | -6.02 | -2.91 | Upgrade
|
| Interest & Investment Income | 2.23 | 3.97 | 7.3 | 3.06 | 2.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 16.59 | 9.29 | -0.1 | -0.02 | -0.55 | Upgrade
|
| EBT Excluding Unusual Items | -75.16 | -108.06 | -190.37 | -182.89 | -65.08 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.24 | -0.69 | -0.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | 80.85 | 5.68 | - | - | - | Upgrade
|
| Other Unusual Items | - | -23.4 | - | - | - | Upgrade
|
| Pretax Income | 5.7 | -125.77 | -190.13 | -183.58 | -65.58 | Upgrade
|
| Earnings From Continuing Operations | 5.7 | -125.77 | -190.13 | -183.58 | -65.58 | Upgrade
|
| Earnings From Discontinued Operations | - | 125.91 | 76.41 | -66.58 | - | Upgrade
|
| Net Income | 5.7 | 0.14 | -113.72 | -250.16 | -65.58 | Upgrade
|
| Net Income to Common | 5.7 | 0.14 | -113.72 | -250.16 | -65.58 | Upgrade
|
| Net Income Growth | 4088.24% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 6 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 6 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 14.16% | 21.40% | 18.44% | 17.86% | 14.93% | Upgrade
|
| EPS (Basic) | 0.64 | 0.02 | -17.77 | -46.29 | -14.30 | Upgrade
|
| EPS (Diluted) | 0.64 | 0.00 | -17.77 | -46.29 | -14.30 | Upgrade
|
| EPS Growth | 14333.92% | - | - | - | - | Upgrade
|
| Free Cash Flow | 0.87 | -148.99 | -125.33 | -238.64 | -2.88 | Upgrade
|
| Free Cash Flow Per Share | 0.10 | -19.18 | -19.58 | -44.16 | -0.63 | Upgrade
|
| Gross Margin | - | - | - | - | 2.10% | Upgrade
|
| Operating Margin | -11910.14% | - | - | - | -44.50% | Upgrade
|
| Profit Margin | 721.93% | - | - | - | -45.25% | Upgrade
|
| Free Cash Flow Margin | 109.63% | - | - | - | -1.99% | Upgrade
|
| EBITDA | -89.84 | -115.85 | -188.85 | -173.29 | -58.55 | Upgrade
|
| EBITDA Margin | - | - | - | - | -40.40% | Upgrade
|
| D&A For EBITDA | 4.13 | 5.47 | 6.24 | 6.63 | 5.95 | Upgrade
|
| EBIT | -93.97 | -121.32 | -195.1 | -179.91 | -64.49 | Upgrade
|
| EBIT Margin | - | - | - | - | -44.50% | Upgrade
|
| Revenue as Reported | 0.79 | - | - | - | 144.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.